Editorial on: Canagliflozin Mediates Mitophagy Through the AMPK/PINK1/PARKIN Pathway to Alleviate Isoprenaline-Induced Cardiac Remodeling

Affiliations

¹ Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, IT.
² Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, IT.
³ Data Collection G-STeP Research Core Facility, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
⁴ Department of Biology, College of Science and Technology, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA.
⁵ Division of Cardiology, Department of Medical Translational Sciences, University of Campania Luigi Vanvitelli, Naples, Italy; and.
⁶ Department of Medicine and Health Sciences "Vincenzo Tiberio", Università degli Studi del Molise, Campobasso, Italy.

Alfredo Caturano et al. J Cardiovasc Pharmacol. 2024.

. 2024 Nov 1;84(5):490-492.

doi: 10.1097/FJC.0000000000001629.

¹ Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, IT.
² Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, IT.
³ Data Collection G-STeP Research Core Facility, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
⁴ Department of Biology, College of Science and Technology, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA.
⁵ Division of Cardiology, Department of Medical Translational Sciences, University of Campania Luigi Vanvitelli, Naples, Italy; and.
⁶ Department of Medicine and Health Sciences "Vincenzo Tiberio", Università degli Studi del Molise, Campobasso, Italy.

No abstract available

Conflict of interest statement

The authors report no conflicts of interest.

1. Neal B, Perkovic V, Mahaffey KW, et al., CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
1. Nevola R, Alfano M, Pafundi PC, et al. Cardiorenal impact of SGLT-2 inhibitors: a conceptual revolution in the management of type 2 diabetes, heart failure and chronic kidney disease. Rev Cardiovasc Med. 2022;23:106.
1. Gong S, Sui Y, Xiao M, et al. Canagliflozin mediates mitophagy through the AMPK/PINK1/PARKIN pathway to alleviate isoprenaline-induced cardiac remodelling. J Cardiovasc Pharmacol. 2024. doi:10.1097/FJC.0000000000001625. - DOI
1. Wang S, Long H, Hou L, et al. The mitophagy pathway and its implications in human diseases. Signal Transduct Target Ther. 2023;8:304.
1. Yang C, Xiao C, Ding Z, et al. Canagliflozin mitigates diabetic cardiomyopathy through enhanced PINK1-parkin mitophagy. Int J Mol Sci. 2024;25:7008.